Podrobný sprievodca čoskoro
Pracujeme na komplexnom vzdelávacom sprievodcovi pre Hyperkalaemia ECG & Treatment Guide. Čoskoro sa vráťte pre podrobné vysvetlenia, vzorce, príklady z praxe a odborné tipy.
Hyperkalaemia-related ECG changes are a series of progressive electrocardiographic abnormalities caused by rising serum potassium concentrations that directly alter cardiac membrane excitability and conduction velocity. Potassium is the principal intracellular cation, and even modest rises in extracellular potassium depolarise the resting membrane potential, altering the sodium channel kinetics responsible for cardiac action potentials. The ECG changes of hyperkalaemia follow a characteristic sequence correlated with potassium levels: peaked (tall, narrow, tent-shaped) T waves are the earliest and most sensitive finding, typically appearing at potassium >5.5 mmol/L; PR interval prolongation and P wave flattening occur at potassium >6.0–6.5 mmol/L; P wave disappearance (sinoventricular conduction replacing SA node activity) occurs at >6.5 mmol/L; progressive QRS widening and the development of a classic 'sine wave' pattern (merging of widened QRS with T waves) occurs at >7.0 mmol/L; and ventricular fibrillation or asystole may occur at potassium >8.0 mmol/L. However, the correlation between ECG findings and serum potassium is imperfect — rate of rise, concurrent medications, calcium levels, and pH all modulate cardiac sensitivity. Treatment of severe or symptomatic hyperkalaemia is a medical emergency and follows a structured sequence: membrane stabilisation with calcium gluconate or calcium chloride IV; intracellular potassium shifting with insulin+dextrose, salbutamol (albuterol) nebulisation, and sodium bicarbonate; enhanced potassium elimination with patiromer, sodium zirconium cyclosilicate, kayexalate, or haemodialysis.
Hyperkalaemia severity: Mild = K+ 5.5–5.9 mmol/L; Moderate = K+ 6.0–6.4 mmol/L; Severe = K+ ≥6.5 mmol/L; ECG thresholds: peaked T waves >5.5; PR prolongation >6.0; P wave loss >6.5; wide QRS/sine wave >7.0; VF/arrest >8.0; Calcium gluconate 10% 10 mL IV over 2–5 min (1 g); Insulin 10 units + 25 g dextrose IV; Salbutamol 10–20 mg nebulised; Sodium bicarbonate 50–100 mEq IV (if acidosis)
- 1Obtain a 12-lead ECG as soon as hyperkalaemia is suspected or confirmed — ECG findings determine the urgency of treatment and guide the sequence of interventions; do not wait for laboratory confirmation before obtaining an ECG in a symptomatic patient.
- 2Assess ECG findings systematically: measure the T wave height and morphology (peaked = tall, narrow, symmetric, tent-shaped vs normal asymmetric); measure the PR interval (normal <200 ms); examine P wave presence and morphology; measure QRS duration (normal <120 ms); look for sine wave pattern or QRS-T merging.
- 3Correlate ECG findings with the serum potassium level and assess for secondary causes: acute kidney injury, medications (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, trimethoprim, heparin), tumour lysis syndrome, rhabdomyolysis, haemolysis, or adrenal insufficiency (Addison's disease).
- 4Initiate calcium gluconate (or calcium chloride) IV immediately for any of: potassium ≥6.5 mmol/L, QRS widening >120 ms, sine wave pattern, or loss of P waves — calcium stabilises cardiac membrane within 1–3 minutes but does not lower potassium; repeat after 5 minutes if ECG has not improved.
- 5Administer potassium-shifting agents to move potassium intracellularly: insulin 10 units IV with 25 g (50 mL of 50%) dextrose (onset 15–30 min); salbutamol 10–20 mg nebulised (beta-2 effect, onset 30 min, lowers K by 0.5–1.0 mmol/L); sodium bicarbonate 50–100 mEq IV if concurrent metabolic acidosis (pH <7.2); these agents are temporising — potassium returns to serum within hours.
- 6Initiate potassium elimination: patiromer (Veltassa) or sodium zirconium cyclosilicate (Lokelma) as oral/NG potassium binders for non-emergency elimination; kayexalate (sodium polystyrene sulphonate) is less preferred due to bowel necrosis risk; haemodialysis is the most effective and fastest method for severe refractory hyperkalaemia, particularly in renal failure.
- 7Monitor potassium hourly for the first 4–6 hours after treatment and repeat ECG after each major intervention; identify and treat the underlying cause to prevent recurrence — the potassium shifting from insulin+salbutamol is transient (4–6 hours).
Peaked T waves are the earliest and most sensitive ECG sign of hyperkalaemia but are not specific — tall T waves also occur in early MI and LVH.
At K+ 5.8 mmol/L with peaked T waves only and normal PR/QRS, the immediate cardiac risk is low; focus on identification and treatment of the underlying cause.
Sine wave pattern precedes ventricular fibrillation; treat as a cardiac emergency regardless of symptoms.
QRS widening to 180 ms with P wave absence indicates severe conduction system toxicity from hyperkalaemia; VF can occur without warning — calcium must be given immediately.
Insulin drives K+ into cells via Na-K-ATPase activation; dextrose is given to prevent hypoglycaemia — monitor blood glucose hourly.
This is the most effective and rapid potassium-shifting intervention; the effect is temporary (lasts 4–6 hours); elimination therapy must be planned concurrently.
Calcium chloride contains 272 mg elemental Ca vs 90 mg in calcium gluconate per 10 mL — calcium chloride acts faster but causes severe tissue necrosis if extravasated.
For peripheral IV access, calcium gluconate is safer; calcium chloride is preferred via CVC in the most severe/arrested scenarios for its faster and more potent cardiac stabilisation.
Professionals in finance and lending use Hyperkalaemia Ecg as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.
University professors and instructors incorporate Hyperkalaemia Ecg into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.
Consultants and advisors use Hyperkalaemia Ecg to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.
Individual users rely on Hyperkalaemia Ecg for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hyperkalaemia ecg calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hyperkalaemia ecg calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in hyperkalaemia ecg calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
| K+ Level (mmol/L) | ECG Change | Risk | Immediate Action |
|---|---|---|---|
| 5.5–5.9 | Peaked T waves | Low | Monitor, treat cause, dietary K restriction |
| 6.0–6.4 | PR prolongation, peaked T waves | Moderate | Monitor ECG, insulin+dextrose, treat cause |
| 6.5–7.0 | P wave disappearance, QRS widening | High | Calcium gluconate IV + insulin+dextrose + salbutamol |
| >7.0 | Sine wave, VT/VF risk | Very High/Emergency | IV calcium immediately + all shifting agents + dialysis |
| >8.0 | VF, asystole | Cardiac Arrest | ACLS + dialysis; all membrane stabilisation agents STAT |
How fast do ECG changes develop in hyperkalaemia?
ECG changes can develop rapidly — within minutes to hours — when potassium rises acutely (e.g., rhabdomyolysis, tumour lysis, succinylcholine administration in susceptible patients). In chronic renal failure with gradual potassium rise, ECG changes may lag considerably behind serum levels due to adaptive changes. This is why clinical context and trend matter as much as the absolute potassium value.
Does calcium actually lower potassium?
No. Calcium gluconate or calcium chloride does not lower serum potassium — it temporarily antagonises the toxic cardiac membrane effects of hyperkalaemia by raising the action potential threshold and restoring the normal resting membrane potential. The protective effect lasts 30–60 minutes. Potassium-lowering agents (insulin, salbutamol, binders, dialysis) must be administered alongside or immediately after calcium.
What is the role of sodium bicarbonate in hyperkalaemia?
Hyperkalaemia Ecg is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
How much does salbutamol (albuterol) lower potassium?
High-dose nebulised salbutamol (10–20 mg) lowers serum potassium by 0.5–1.0 mmol/L within 30–60 minutes via beta-2 receptor stimulation of Na-K-ATPase. It is additive to insulin; using both simultaneously produces a 1.0–1.5 mmol/L combined reduction. Note: 10–20 mg is 4–8× higher than a standard asthma bronchodilator dose and may cause tremor and tachycardia.
When does hyperkalaemia require emergency haemodialysis?
Haemodialysis is indicated for: potassium >6.5–7.0 mmol/L with refractory ECG changes; potassium >7.0 mmol/L in renal failure; haemodynamic instability from hyperkalaemia-induced arrhythmia; or failure of medical management (insulin, salbutamol, binders) to lower potassium within 1–2 hours. It is the most effective elimination method, lowering potassium by 1–2 mmol/L per hour of dialysis.
What causes pseudohyperkalaemia?
Pseudohyperkalaemia is a falsely elevated potassium from in-vitro cell lysis: haemolysed blood samples (from rough venepuncture or prolonged tourniquet), extreme thrombocytosis (platelets release K during clotting in serum samples), extreme leucocytosis, or delayed sample processing at high ambient temperatures. Always repeat the test with a fresh, atraumatic sample and use a plasma (heparinised) tube rather than serum if pseudohyperkalaemia is suspected.
Can succinylcholine cause hyperkalaemia?
Yes. Succinylcholine causes a predictable 0.5–1.0 mmol/L rise in serum potassium in normal patients due to muscle depolarisation. In patients with denervation injuries (paraplegia, burns, immobility, stroke, Guillain-Barré) who have undergone extrajunctional acetylcholine receptor upregulation, succinylcholine can trigger catastrophic hyperkalaemia (potassium rising to 7–10 mmol/L) causing cardiac arrest. It is absolutely contraindicated in these patients.
What medications commonly cause hyperkalaemia?
In the context of Hyperkalaemia Ecg, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Pro Tip
The pneumonic 'C BIG K Drop' helps recall hyperkalaemia treatment: Calcium (membrane stabilisation); Bicarbonate (if acidotic); Insulin + Glucose; potassium-binding resins (Kayexalate/patiromer); Dialysis. Apply them in this sequence — stabilise the heart first, then shift potassium, then eliminate it.
Did you know?
The cardiac conduction system is so sensitive to potassium that anaesthesiologists use potassium-containing cardioplegia solutions (high-K+ cold crystalloid or blood cardioplegia at 15–40 mmol/L K+) to deliberately arrest the heart during open-heart surgery. The heart is then restarted with normal electrolyte warm blood reperfusion — a beautiful clinical application of the same physiology that makes hyperkalaemia so dangerous.
References
- ›Kovesdy CP — Epidemiology of hyperkalemia: an update (Kidney International Supplements, 2016)
- ›Elliott MJ et al. — Management of patients with acute hyperkalaemia (BMJ, 2010)
- ›Alfonzo A et al. — UK Renal Association Clinical Practice Guidelines: Hyperkalaemia (2020)
- ›Peacock WF et al. — Sodium zirconium cyclosilicate (ZS-9) in emergency management of hyperkalaemia (ACEP 2021)
- ›Sterns RH et al. — Treatment of hyperkalaemia: what are the options? (Seminars in Nephrology, 2016)